|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XE28
|
|
gptkbp:brand
|
gptkb:Zykadia
|
|
gptkbp:CASNumber
|
1032900-25-6
|
|
gptkbp:chemicalFormula
|
C28H36N5O3Cl
|
|
gptkbp:contraindication
|
hypersensitivity to ceritinib
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
41 hours
|
|
gptkbp:form
|
capsule
|
|
gptkbp:genericName
|
gptkb:ceritinib
|
|
gptkbp:indication
|
ALK-positive metastatic non-small cell lung cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
ALK inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
97.1%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
fatigue
increased liver enzymes
|
|
gptkbp:target
|
gptkb:anaplastic_lymphoma_kinase_(ALK)
|
|
gptkbp:bfsParent
|
gptkb:ceritinib
gptkb:Ceritinib
|
|
gptkbp:bfsLayer
|
7
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
Zykadia
|